Replies to post #398574 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Blarcamesine’s prophylactic powers will be incidentally recognized.

It is a real possibility that 2-73 may become a prophylactic use drug. That won't happen any time soon since such a trial would be multiple years long I suspect

Actually, prophylactic use of blarcamesine may be validated and proven without a separate, lengthy clinical trial for such. This could be the scenario (which will take some time itself).

When the drug finally becomes a first-line, standard of care (SOC) treatment for both Alzheimer’s and Parkinson’s it will be eventually discovered that patients taking blarcamesine have two separate but related outcomes.

First, of course, will be the halting or reversal of the progression of both of those diseases. Termination of symptomatic progression, disease worsening, will be most evident in patients with the earliest, least severe disease stages. It will become obvious that the earlier either disease is treated with blarcamesine the more favorable the clinical outcomes. It will then stand to reason to start blarcamesine therapy in patients who don’t have any symptoms at all, but have been detected to have genetic or physiological destinies for them.

But secondly it will be discovered that Alzheimer’s or Parkinson’s disease patients with on-going, successful blarcamesine treatments gain relief not only from those target diseases but because of blarcamesine’s facilitation of sound sleep and restoration of normal cell-keeping processing in neurons and other cells those patients will also experience increased general health. While on blarcamesine they don’t age at typical rates. Their mental and physical health is dramatically improved. It then becomes obvious this would also occur in people being dosed with blarcamesine who don’t have specific, developed CNS debilities.

Blarcamesine’s therapeutic, even prophylactic powers will be difficult not to recognize and implement..

[bas2020]

Once approved, blarcamesine will certainly be prescribed to patients who exhibit any potential signs of AD